Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently recruiting participants for a Phase 2 study titled ‘A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis.’ The study aims to evaluate the efficacy and safety of targeted therapies, specifically risankizumab and lutikizumab, in treating active psoriatic arthritis and assessing changes in disease symptoms. This research is significant as it could lead to improved treatment options for individuals suffering from this chronic condition.
The study involves three treatment arms: lutikizumab monotherapy, risankizumab monotherapy, and a combination therapy of both drugs. Each drug is administered via subcutaneous injection, aiming to reduce symptoms associated with psoriatic arthritis.
The study design is interventional with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment. Approximately 120 participants will be enrolled across 40 sites worldwide.
The study began on April 11, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 5, 2025. These timelines are crucial for investors to track the progress and potential market entry of these therapies.
The market implications of this study are significant for AbbVie, as successful results could enhance their portfolio in the immunology sector, potentially boosting their stock performance. Investors should also consider the competitive landscape, as advancements in psoriatic arthritis treatments could impact market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.